Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

AZD2066

Generic Name: AZD2066

Drug Type: Small Molecule

Chemical Formula: C_₁₉H_₁₆ClN_₅O_₂

CAS Number: 934282-55-0

Unique Ingredient Identifier: MQ908Y1ZB2

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

6-week Study Treatment to Evaluate the Safety and Effectiveness of AZD2066 in Patients With Major Depressive Disorder

Phase 2

Terminated

Posted: 2010/06/17

Sponsor:AstraZeneca

ID:NCT01145755

AZD2066 Neuropathic Pain - Mechanical Hypersensitivity

Phase 2

Terminated

Posted: 2009/07/14

Sponsor:AstraZeneca

ID:NCT00939094

AZD2066 Cocktail Study

Phase 1

Completed

Posted: 2009/06/30

Sponsor:AstraZeneca

ID:NCT00930306

Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy

Phase 2

Completed

Posted: 2009/03/06

Sponsor:AstraZeneca

ID:NCT00857623

Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066

Phase 1

Completed

Posted: 2009/01/26

Sponsor:AstraZeneca

ID:NCT00829088

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy